Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Phys Rev Lett ; 84(8): 1651-4, 2000 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-11017592

RESUMO

Cross sections for the 44Ti(alpha,p)47V reaction which significantly affects the yield of 44Ti in supernovae were measured in the energy range 5.7 MeV

5.
Cancer Treat Rep ; 68(7-8): 1019-21, 1984.
Artigo em Inglês | MEDLINE | ID: mdl-6204753

RESUMO

Thirty-three patients with stage III-IV squamous cell carcinoma of the head and neck previously untreated with chemotherapy or radiotherapy were given a multidrug cytotoxic regimen, VBM (vincristine, bleomycin, and methotrexate), in combination with radical radiotherapy. Of the 32 evaluable patients, 11 (34.4%) achieved clinical complete response with negative biopsy, 15 (46.8%) achieved partial response, three (9.4%) had no change, and three (9.4%) had disease progression. At 30 months, the actuarial survival rate for complete responders with negative biopsy was 62.2% and the overall survival rate was 30.8%. Hematologic and gastrointestinal toxicity was moderate, but one patient developed life-threatening mucositis and one patient died due to acute renal failure. Our data do not confirm prior more favorable results obtained with the same treatment.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/terapia , Neoplasias de Cabeça e Pescoço/terapia , Adulto , Idoso , Bleomicina/efeitos adversos , Bleomicina/uso terapêutico , Carcinoma de Células Escamosas/radioterapia , Terapia Combinada , Feminino , Neoplasias de Cabeça e Pescoço/radioterapia , Humanos , Masculino , Metotrexato/efeitos adversos , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Vincristina/efeitos adversos , Vincristina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA